<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00417183</url>
  </required_header>
  <id_info>
    <org_study_id>long vs flexible</org_study_id>
    <nct_id>NCT00417183</nct_id>
  </id_info>
  <brief_title>Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation</brief_title>
  <official_title>Randomized Controlled Trial Comparing the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation in Normal Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eugonia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eugonia</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of two controlled ovarian stimulation
      protocols, the GnRH agonist protocol, widely known as the &quot;long&quot; protocol, and the flexible
      GnRH antagonist protocol, in terms of pregnancy rates and embryological data, in infertile
      patients receiving IVF treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The formulation of controlled ovarian stimulation protocols is one of the primary reasons for
      the successful development of IVF. The &quot;long&quot; GnRH agonist protocol, also known as the gold
      standard, has been widely used with considerable success. More recently, on the other hand,
      GnRH antagonist provide a new promising approach for endogenous gonadotrophin suppression by
      blocking the GnRH receptor. There is conflicting data in the literature regarding the
      relative merits of the two ovarian stimulation protocols.

      COMPARISON: Pregnancy rates and embryological data will by assessed in IVF patients treated
      with either the &quot;long&quot; GnRH agonist (Arvekap) or the flexible GnRH antagonist (Ganirelix)
      protocol.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date>June 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy per embryo transfer</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy per embryo transfer</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy per embryo transfer</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryological data</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Infertility</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arvekap 0.1 mg (Triptorelin, Ipsen, France)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-39 years

          -  Body mass index 18-29 kg/m2

          -  Menstrual cycle from 24-35 days

          -  Normal basal FSH (&lt;10 IU/ml)

          -  Normal basal LH (&lt;10 IU/ml)

          -  Normal basal estradiol (&lt;80 pg/ml)

        Exclusion Criteria:

          -  Poor responder patients

          -  Polycystic ovaries
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tryfon Lainas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eugonia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tryfon Lainas, PhD</last_name>
    <phone>00302107236333</phone>
    <email>ivf@eugonia.com.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eugonia</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tryfon Lainas, PhD</last_name>
      <phone>00302107236333</phone>
      <email>ivf@eugonia.com.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Lainas T, Zorzovilis J, Petsas G, Stavropoulou G, Cazlaris H, Daskalaki V, Lainas G, Alexopoulou E. In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF. Hum Reprod. 2005 Sep;20(9):2426-33. Epub 2005 Jun 9.</citation>
    <PMID>15946995</PMID>
  </reference>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2006</study_first_submitted>
  <study_first_submitted_qc>December 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2006</study_first_posted>
  <last_update_submitted>December 28, 2006</last_update_submitted>
  <last_update_submitted_qc>December 28, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2006</last_update_posted>
  <keyword>GnRH antagonist</keyword>
  <keyword>GnRH agonist</keyword>
  <keyword>Long protocol</keyword>
  <keyword>Flexible</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

